Cipla BioTec Information

Less than 8% patients eligible for biopharmaceutical treatment worldwide receive the treatment they need. While many believe this is an emerging markets issue, biopharmaceutical penetration in the US and Europe stands at less than 30%. In many cases, patients are unable to receive biopharmaceutical treatment because of exorbitant costs of these medicines which can be as high as USD 40,000 per year. Biosimilars are now approved in all major markets. Examples of biosimilar launches in European markets have shown that prices drop by as much as 60% with usage increasing significantly as high quality more affordable biosimilars become available. Cipla BioTec (CBT) is a research, development, manufacturing and marketing organization focusing on biosimilar products. CBT is backed by Cipla, a global pharmaceutical company with ~USD 2 bn revenue from operations in more than 100 countries and a market capitalization of ~USD 6 bn. Cipla is best known for introducing HIV / AIDS therapy at USD 1 / day, enabling treatme